Single-cell sequencing in primary intraocular tumors: understanding heterogeneity, the microenvironment, and drug resistance

Front Immunol. 2023 Jun 9:14:1194590. doi: 10.3389/fimmu.2023.1194590. eCollection 2023.

Abstract

Retinoblastoma (RB) and uveal melanoma (UM) are the most common primary intraocular tumors in children and adults, respectively. Despite continued increases in the likelihood of salvaging the eyeball due to advancements in local tumor control, prognosis remains poor once metastasis has occurred. Traditional sequencing technology obtains averaged information from pooled clusters of diverse cells. In contrast, single-cell sequencing (SCS) allows for investigations of tumor biology at the resolution of the individual cell, providing insights into tumor heterogeneity, microenvironmental properties, and cellular genomic mutations. SCS is a powerful tool that can help identify new biomarkers for diagnosis and targeted therapy, which may in turn greatly improve tumor management. In this review, we focus on the application of SCS for evaluating heterogeneity, microenvironmental characteristics, and drug resistance in patients with RB and UM.

Keywords: heterogeneity; microenvironment; retinoblastoma; single-cell sequencing; uveal melanoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • Drug Resistance
  • Humans
  • Melanoma* / pathology
  • Prognosis
  • Tumor Microenvironment / genetics
  • Uveal Neoplasms* / drug therapy
  • Uveal Neoplasms* / genetics
  • Uveal Neoplasms* / pathology

Supplementary concepts

  • Uveal melanoma

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (81570885 and 81770959), Talent Development Program of Changzheng Hospital (YQ722), Youth Initial Found of Naval Medicine University (2022DN078), and Foundation of Shanghai Health Bureau (201402014).